Please login to the form below

Not currently logged in
Email:
Password:

Kadcyla

This page shows the latest Kadcyla news and features for those working in and with pharma, biotech and healthcare.

Roche preps new Kadcyla filings after phase 3 trial win

Roche preps new Kadcyla filings after phase 3 trial win

Roche preps new Kadcyla filings after phase 3 trial win. Says the drug significantly reduced IDFS in women with residual disease. ... Now, Roche has clinical data showing its antibody-drug conjugate Kadcyla offers a second-line of treatment for these

Latest news

More from news
Approximately 15 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Positive disruption in business intelligence Positive disruption in business intelligence

    Take the recent recommendation by NICE, the UK’s drug-spending policymaker, of Kadcyla, the breast cancer treatment launched by Roche. ... In December 2016, NICE issued draft guidance indicating Kadcyla was too expensive for routine funding on the NHS.

  • Back to the future Back to the future

    and Kadcyla.

  • Pharma deals during August 2013 Pharma deals during August 2013

    Proof-of-concept has been established with Genentech's Kadcyla currently marketed in the US.

  • Pharma deals during April 2013 Pharma deals during April 2013

    This passion has seemingly been ignited further by the recent FDA approvals of Kadcyla (Genentech/ ImmunoGen) and Adcetris (Seattle Genetics) both following impressive clinic trials in HER2 breast cancer and lymphoma,

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics